A Montreal study, to which research member Dr. Moishe Liberman contributed, shows that a drug increases the chances of survival for patients with non-small cell lung cancer (NSCLC), the most common form of lung cancer.
The drug, which restores the anti-tumor immune response, is combined with chemotherapy and administered before surgery.
The results of this study were published in the prestigious New England Journal of Medicine.
Other news
![Non-small cell lung cancer: a breakthrough in treatment](https://www.icm.qc.ca/wp-content/uploads/2020/11/istock-1044233084-1600x1600.jpg)
Subscribe to our newsletter
Thank you, we have received your registration
Sorry, an error occurred
![](https://www.icm.qc.ca/wp-content/themes/icm/assets/img/ajax-loader.gif)